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Indwelling Pleural Catheter
Changing the Paradigm of Malignant Effusion Management
Y. C. Gary Lee, FRACP, and Edward T. H. Fysh, MBBS
Malignant pleural effusions (MPEs) affect as many as 150,000 patients with cancer inthe United States1 and 100,000 patients with lung cancer2 in Europe each year.
Inpatient care alone for MPE costs US$6 million per million population in Australia
annually (data, the Western Australia Health Dept). The exciting advent of indwelling
tunneled pleural catheters (IPCs) has critically challenged conventional approaches to MPE
management, especially pleurodesis.3 IPCs offer ambulatory fluid drainage as the primary
symptomatic therapy, thus prompting clinicians to redefine the goalposts of MPE care.
Talc pleurodesis has been the mainstay of MPE management for decades, but its
efficacy and safety have recently come under scrutiny.4 In the largest randomized trial in
pleural disease (n 486),5 talc (poudrage or slurry) pleurodesis had a suboptimal success rate:
only 75% of MPE patients at 1 month and 50% by 6 months had adequate fluid control.
Adding the fact that many patients are unsuitable for pleurodesis (e.g., with trapped lungs), talc
pleurodesis benefits only a subset of all MPE patients. Randomized trials have also shown that
talc induces lung and systemic inflammation6 and killed 2.3% of patients in a Cancer and
Leukemia Group B study through talc-induced respiratory failure.5 Although this acute lung
injury can be avoided by using large particle size talc preparations,7 such products are not
readily available in many countries, including the United States.
These data have provoked debates and compelled the pleural community to revisit
the principles of MPE care. The fundamental aim in MPE management is to improve
dyspnea and quality of life, with minimal intervention and hospitalization. The timely
introduction of IPCs which allow fluid evacuation from a single minimally invasive
procedure serves exactly this purpose and explains its rapid rise in popularity (Suzuki
et al estimated that 39,000 units sold in the United States per year8).
Suzuki et al.8 in this issue of Journal of Thoracic Oncology reported the largest
series of IPC (n  418) experience, providing corroborative evidence that IPCs are
safe.9–12 A recent summary of all published reports on IPC complications revealed that
most complaints were minor (e.g., mild pain after insertion).13 A systematic review
including 1370 patients has confirmed that serious complications, e.g., infection were
uncommon (3%).14 Other series have addressed specific concerns of IPC use: demon-
strating safety records in patients undergoing chemotherapy15 and local radiotherapy16
with IPC in situ, and no significant protein loss results from regular drainage.17
IPC represents a new therapeutic ideology (not “yet another catheter”), and clini-
cians are still adapting to the specific changes needed to realize the full potential of this
device. Suzuki et al.8 described a representative single-center review of IPC use,
highlighting important contemporary issues of IPC management.
First, the exact place of IPC in the paradigm of MPE management has yet to be
defined. IPC is generally accepted for treatment of MPE patients in whom pleurodesis has
failed or is contraindicated (especially trapped lungs).18 Many specialist centers now offer
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IPC as the first-choice therapy in place of talc pleurodesis,
among growing recognition ofits limitations. There are, how-
ever, no head-on comparisons between these two strategies. This
issue is being addressed by a multicenter randomized trial in the
United Kingdom (near completion) and one planned in the
Netherlands that compare IPC versus talc pleurodesis as first-
line therapy in MPE patients. Until the results are available, the
debate will continue. Patients, in the meantime, should be
allowed to make an informed choice of treatment that best meets
individual needs. Clinicians have to have knowledge of the
pros/cons of each therapy to guide patient decisions.
Second, aftercare of IPC is crucial to its effective and safe
employment. A dedicated IPC service, already available in
selected centers, is recommended. Clinicians prescribing IPC
treatment must be committed to its ongoing care, akin to peri-
toneal (dialysis) catheter. As reported by Suzuki et al.,8 IPCs are
often inserted (even within one center) by different specialists:
surgeons, radiologists, or pulmonologists, many of whom do not
have infrastructure established to provide community support
and close follow-ups. A centralized IPC service allows clinicians
to gain expertise and avoid dilution of experience during the
active learning phase. IPCs managed by a specialist pleural
center have significantly fewer complications (Fysh et al., un-
published data). Growing numbers of specialist centers are
developing dedicated pleural services (see review in Ref. 19) to
provide efficient and safe pleural procedural services.20 These
pleural units will be best placed to deliver IPC care.
Third, IPC signals the arrival of symptom-directed palli-
ative therapy in MPE. “Success” must now be defined by
patient-oriented parameters. The conventional measurement of
“success” by pleurodesis rate, often measured by absence of
fluid on radiographs, is of peripheral importance. Suzuki et al.8
defined success as no further effusion-related drainage proce-
dure; it is a step toward the right direction, and their success rate
of 91% with IPC was encouraging. The priority for most MPE
patients are alleviation of dyspnea and optimization of quality of
life (the principle end points for aforementioned European mul-
ticenter trials) while avoiding hospital admissions (end point of
the Western Australian State Health Research Advisory Council
pilot study). These parameters should be considered new goal-
posts for MPE care and research.
The full potential and impact of IPCs on the paradigm
of pleural effusion management are only beginning to be
realized. Past studies have suggested that ambulatory sclero-
therapy can be performed by small bore catheters when the
initial effusion has been drained.21 IPCs can also be used after
thoracoscopy to speed up discharge.22 The indication for IPC
has been extended to other recurrent effusions, including hepatic
hydrothorax,23 chronic empyema,24 and chylothorax.17 In the
long run, IPCs may be used as a one-stop procedure for patients
presenting with a suspected MPE, providing both diagnostic and
therapeutic drainage as well as definitive MPE management, if
cytology confirms malignancy.
Pleurodesis, from the scientific standpoint, is an unso-
phisticated crude act. Mechanical or chemical pleurodesis
work by damaging the pleura, which heals with inflammation,
scarring, and pleural symphysis.25 The more severe the pleu-
ral injury is, the greater the likelihood of achieving pleurodesis.
Over three quarters of a century after the description of talc
poudrage,26 IPC provides a viable alternative that avoids muti-
lation of the pleura. Nevertheless, the ultimate goal in MPE
management remains to stop the fluid formation, which can
negate the need for either IPC or pleurodesis. Antiangiogenics
have shown great promise in preclinical models, but clinical
proofs are lacking.27 In this era of individualized targeted cancer
therapy, management of MPE remains relatively primitive and
should be regarded a high priority in cancer research.
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